<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03157414</url>
  </required_header>
  <id_info>
    <org_study_id>2016/911</org_study_id>
    <secondary_id>2016-001705-17</secondary_id>
    <secondary_id>2016069</secondary_id>
    <nct_id>NCT03157414</nct_id>
  </id_info>
  <brief_title>Empagliflozin in Renal Transplant Recipients</brief_title>
  <acronym>EMPA-RenalTx</acronym>
  <official_title>Efficacy and Safety of Empagliflozin in Renal Transplant Recipients With Post-transplantation Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, prospective, controlled, double-blind, randomized study. A total of
      50 renal transplant recipients diagnosed with post-transplantation diabetes mellitus (PTDM)
      will be included more than 1 year after transplantation and radomized 1:1 to empagliflozin
      (Jardiance®) 10 mg or placebo once daily for 24 weeks. Patients with estimated glomerular
      filtration rate below 30 mL/min will be excluded. Oral glucose tolerance test, 72h continuous
      glucose monitoring (iPro™2), measurement of arterial stiffness, body composition (including
      visceral fat), 24h blood pressure and 24h urinary glucose excretion will be performed at
      baseline and after 24 weeks in addition to standard safety measurements. Two safety visits
      will be performed at week 8 and 16. All concomitant medication, diet and exercise will be
      kept stable during the study period. The objective of the present study is to answer whether
      empagliflozin safely and effectively improves glucose metabolism together with weight loss in
      renal transplant recipients with PTDM.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Weighted mean glucose</measure>
    <time_frame>24 weeks</time_frame>
    <description>The primary endpoint will be change from baseline in weighted mean glucose at week 24 compared to placebo. Each patient will perform continuous plasma glucose monitoring (CGM, iProTM2) for 72 hours at baseline and after 24 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting plasma glucose</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change from baseline in fasting plasma glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2 hour glucose concentration</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change from baseline in 2 hour glucose concentration after an oral glucose tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycated hemoglobin (HbA1c)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change from baseline in HbA1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change from baseline in body weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist-hip-ratio</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change from baseline in waist-hip-ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone mineral density</measure>
    <time_frame>24 weeks</time_frame>
    <description>Measurement of bone mineral density, using low dosage radiation (dual-energy X-ray absorptiometry (DEXA) scan) to assess the amount (grams) of mineral that are packed into a segment of bone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition</measure>
    <time_frame>24 weeks</time_frame>
    <description>Body composition (visceral fat, metabolic measurement) will be determined using the software CoreScan (encore version 14.10, GE Healthcare) on the DEXA scans. This will allow us to analyze changes in body fat compartments to explain overall weight reduction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change from baseline in blood pressure, including orthostatic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial stiffness</measure>
    <time_frame>24 weeks</time_frame>
    <description>Pulse wave velocity, using a SphygmoCor device, measuring arterial stiffness will be performed in addition to pulse wave analysis evaluating the shape and amplitude of the aortic pulse wave</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>24 weeks</time_frame>
    <description>Renal function, defined as glomerular filtration rate (GFR), will be evaluated by creatinine and cystatin C-based estimated GFR using the chronic kidney disease epidemiology collaboration (CKD-EPI) formula. Fasting plasma creatinine and Cystatin C will be drawn at the same time and analyses will be performed at the Hospital central laboratory</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of abnormal trough levels of immunosuppressive drugs</measure>
    <time_frame>24 weeks</time_frame>
    <description>Trough levels of immunosuppressive drugs (tacrolimus); number of participants with abnormal laboratory values</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse event</measure>
    <time_frame>24 weeks</time_frame>
    <description>Recording of adverse events that are related to treatment</description>
  </other_outcome>
  <other_outcome>
    <measure>Urinary glucose excretion</measure>
    <time_frame>24 weeks</time_frame>
    <description>24 hour urine sampling at baseline and after 24 weeks to analyse change in urinary glucose excretion</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Renal Insufficiency</condition>
  <condition>Safety Issues</condition>
  <arm_group>
    <arm_group_label>Empagliflozin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 mg once daily for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 capsule once daily for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin</intervention_name>
    <description>Empagliflozin tablets enclosed with red capsules (Capsugel AAEL) by Kragerø Tablettproduksjon AS for blinding purpose</description>
    <arm_group_label>Empagliflozin</arm_group_label>
    <other_name>Jardiance</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets made by Kragerø Tablettproduksjon AS and enclosed with red capsules (Capsugel AAEL) for blinding purpose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Renal transplant recipient transplanted more than 1 year ago

          -  Stable renal function (&lt;20% deviation in serum creatinine within last 2 months)

          -  Stable immunosuppressive therapy ≥3 months before inclusion

          -  Diagnosed with PTDM:

        (fasting plasma glucose ≥7.0 mmol/l and/or 2-hour plasma glucose ≥11.1 mmol/l following an
        oral glucose tolerance test)

        -Signed informed consent and expected cooperation of the patients

        Exclusion Criteria:

          -  Estimated GFR &lt;30 ml/min/1.73 m2

          -  Pregnant or nursing mothers

          -  Hypersensitivity to the active substance (IMP) or to any of the excipients

          -  Any reason why, in the opinion of the investigator, the patient should not participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Thea AS Halden, PhD</last_name>
    <phone>004723073544</phone>
    <email>t.a.s.halden@medisin.uio.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Trond Jenssen, Professor</last_name>
    <email>tjenssen@ous-hf.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Oslo University Hospital Rikshospitalet</name>
      <address>
        <city>Oslo</city>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thea AS Halden, PhD</last_name>
      <phone>004723073544</phone>
      <email>t.a.s.halden@medisin.uio.no</email>
    </contact>
    <investigator>
      <last_name>Trond Jenssen, Professor, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thea AS Halden, MSc.Pharm, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kine E Kvitne, MSc.Pharm</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karsten Midtvedt, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anders Åsberg, Professor, MSc.Pharm, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anders Hartmann, Professor, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2017</study_first_submitted>
  <study_first_submitted_qc>May 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2017</study_first_posted>
  <last_update_submitted>May 15, 2017</last_update_submitted>
  <last_update_submitted_qc>May 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Trond Jenssen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

